Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
Completed
GlaxoSmithKline
Phase 3
2003-11-01
This study will investigate the efficacy and safety of treatment with dutasteride and
tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement
of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic
Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits).
Transrectal ultrasound (TRUS) is done annually.
Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer
Completed
GlaxoSmithKline
Phase 3
2005-11-01
The purpose of this study is to determine whether a drug named tamsulosin (Flomax), or
another drug named dutasteride (Avodart), or a combination of these two drugs is effective in
improving urinary symptoms and decreasing the rate of intermittent self-catheterization after
prostate brachytherapy.
Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer
Completed
Case Comprehensive Cancer Center
Phase 3
2005-11-01
The purpose of this study is to determine whether a drug named tamsulosin (Flomax), or
another drug named dutasteride (Avodart), or a combination of these two drugs is effective in
improving urinary symptoms and decreasing the rate of intermittent self-catheterization after
prostate brachytherapy.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
